<DOC>
	<DOCNO>NCT00282607</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy safety DA-8159 , orally administer , potent selective inhibitor PDE5 , versus placebo treatment subject erectile dysfunction ( ED ) .</brief_summary>
	<brief_title>A Study DA-8159 Subjects With Erectile Dysfunction</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , parallel-group study 300 erectile dysfunction patient . Patients complete screen visit ( V1 ) determine eligibility study base International Index Erectile Function ( IIEF ) erectile function ( EF ) domain score , patient history safety measure . Patients meet entrance criterion study enter 4 week , drug-free run-in period establish baseline erectile function domain score meet criterion participation study . Patients successfully complete screen randomly assign one four treatment group Visit 2 ( V2 ) : placebo one 3 active drug dose DA-8159 tablet . Patients give medication at-home use also give diary record information regard sexual encounter , quality erection adverse event . At 4-week interval 3 month ( V3 , V4 , V5 ) , patient return clinic review collect SEP diary , safety data , 12-lead ECG medication reconciliation . In addition , 4-week interval patient complete IIEF , Visit 5 blood drawn safety evaluation . The primary efficacy end point : ) change score ( baseline Visit 5 ) Erectile Function domain score IIEF , b ) change response , relative baseline , sexual encounter profile ( SEP ) question 2 , c ) change response , relative baseline , SEP question 3 . For DA-8159 tablet judge efficacious , DA-8159 tablet group must show superior placebo group three measure .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Is male least 19 year age . 2 . Has stable monogamous relationship least 6 month consent female partner ( vaginal intercourse require study activity ) . 3 . Provides write informed consent . 4 . The subject ’ female partner provide write informed consent . 5 . Has history ED ( clinically define inability attain maintain erection penis sufficient permit satisfactory sexual intercourse ) least 3 month duration . The investigator record etiology ED ( organic , psychogenic mixed ) . 6 . Has score 625 Erectile Function domain score ( Questions Number 15 , 15 ) Visits 1 &amp; 2 . 7 . Completes least four diary entry Visit 2 , show least 4 attempt sexual intercourse 50 % great failure rate achieve maintain erection sufficient complete intercourse ( define answer “ ” SEP question # 2 # 3 ) . 8 . The subject ’ partner pregnant lactating subject partner agree use medically acceptable form birth control . Exceptions would subject vasectomy partner post menopausal , partner tubal ligation hysterectomy . 1 . Has history stroke , myocardial infarction , coronary artery disease within past 6 month . 2 . Has history cardiac failure , angina , lifethreatening arrhythmia within past 6 month . 3 . Is take nitrate medication form ( Appendix 7 ) 4 . Is take alpha blocker . 5 . Has clinically significant abnormal laboratory value determine principal investigator . 6 . Has history uncontrolled diabetes ( HbA1c &gt; 9 % ) . 7 . Has history proliferative diabetic retinopathy . 8 . Has history spinal cord injury radical prostatectomy radical pelvic surgery . 9 . Has supine blood pressure low 90/50mmHg uncontrolled hypertension high 170/100mmHg . 10 . Has anatomical deformity penis severe penile fibrosis Peyronie ’ disease . 11 . Has thyroid stimulate hormone ( TSH ) level lower 30 % LLN . 12 . Has erectile dysfunction cause neurological endocrine factor hyperprolactinemia low serum testosterone level ( &lt; 300 ng/dl ) . 13 . Has hepatic impairment ( GOT , GPT level &gt; 3 x ULN ) . 14 . Has renal impairment ( serum creatinine ≥ 2.5mg/dl ) . 15 . Has history hematological disorder bleed disorder risk GI bleed peptic ulceration . 16 . Has history retinitis pigmentosa . 17 . Has history sickle cell disease , multiple myeloma , leukemia disorder may cause priapism . 18 . Has history significant psychiatric disorder . 19 . Has history central nervous system disorder stroke , transient ischemic attack , spinal cord injury . 20 . Has history drug abuse ( alcohol , marijuana , cocaine , opiates ) . 21 . Has know sensitivity drug especially phosphodiesterase type 5 inhibitor Viagra , Cialis Levitra . 22 . Has use erectile dysfunction therapy include nutraceutical herbal product within 14 day prior enter study . 23 . Is use concomitant medication know suspected interact PDE 5 inhibitor follow : 1 . Antibacterial : erythromycin 2 . Antifungals : itraconazole , ketoconazole 3 . Antivirals : ritonavir , saquinavir , amprenavir , indinavir , nelfinavir 4 . H2 receptor antagonist : cimetidine 5 . Anticoagulants , androgen , trazodone 24 . Have sexual disorder hypoactive sexual desire . 25 . Have previously fail respond PDE5 inhibitor Viagra , Cialis Levitra . 26 . Have major illness opinion investigator would interfere conduct study . 27 . Has participate clinical drug study within last 30 day prior enter study .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Erectile Dysfunction</keyword>
</DOC>